PUBLISHER: The Business Research Company | PRODUCT CODE: 1955475
PUBLISHER: The Business Research Company | PRODUCT CODE: 1955475
In vitro diagnostics (IVD) enzymes are specialized proteins utilized in diagnostic tests performed outside the living body, most commonly in laboratory environments. These enzymes catalyze specific biochemical reactions that enable the detection, measurement, or monitoring of various substances, including pathogens, biomarkers, and other molecules important for disease diagnosis.
The main enzyme types in the in vitro diagnostics enzymes market include proteases, polymerases and transcriptases, ribonucleases, and other enzyme categories. Proteases are enzymes that facilitate the breakdown of proteins into smaller peptides or amino acids. These enzymes are applied across a wide range of disease areas, including infectious diseases, diabetes, oncology, cardiology, nephrology, autoimmune disorders, and others. They are involved in multiple technologies such as histology assays, molecular diagnostics, clinical chemistry, and other platforms, and are used by diverse end users including pharmaceutical and biotechnology companies, hospitals and diagnostic laboratories, contract research organizations (CROs), and academic laboratories.
Tariffs have impacted the in vitro diagnostics enzymes market by increasing the cost of imported enzyme raw materials, reagents, and specialized laboratory inputs required for diagnostic kit manufacturing. These effects have been most evident in molecular diagnostics and infectious disease testing segments, particularly in North America and Europe where enzyme sourcing is globally diversified. Asia-Pacific manufacturers have experienced supply chain delays due to trade dependencies. However, tariffs have encouraged regional enzyme production and localized reagent manufacturing, supporting supply resilience and cost optimization.
The in vitro diagnostics enzymes market research report is one of a series of new reports from The Business Research Company that provides in vitro diagnostics enzymes market statistics, including in vitro diagnostics enzymes industry global market size, regional shares, competitors with a in vitro diagnostics enzymes market share, detailed in vitro diagnostics enzymes market segments, market trends and opportunities, and any further data you may need to thrive in the in vitro diagnostics enzymes industry. This in vitro diagnostics enzymes market research report delivers a complete perspective of everything you need, with an in-depth analysis of the current and future scenario of the industry.
The in vitro diagnostics enzymes market size has grown strongly in recent years. It will grow from $2.3 billion in 2025 to $2.48 billion in 2026 at a compound annual growth rate (CAGR) of 7.8%. The growth in the historic period can be attributed to longstanding use of enzymes in clinical chemistry assays, expansion of laboratory-based diagnostic testing, widespread adoption of pcr and molecular diagnostics, growth of hospital and diagnostic laboratory infrastructure, increased screening for infectious and chronic diseases.
The in vitro diagnostics enzymes market size is expected to see strong growth in the next few years. It will grow to $3.25 billion in 2030 at a compound annual growth rate (CAGR) of 7.0%. The growth in the forecast period can be attributed to rising prevalence of infectious and chronic diseases, increasing demand for rapid and accurate diagnostics, expansion of decentralized and point-of-care testing, growth in personalized and precision diagnostics, rising investment in advanced molecular diagnostic technologies. Major trends in the forecast period include rising demand for high-specificity enzymes in molecular diagnostics, growing use of enzymes in infectious disease testing panels, increasing adoption of enzyme-based point-of-care diagnostics, expansion of multiplex diagnostic assays using enzyme systems, greater focus on enzyme stability and shelf-life optimization.
The increasing prevalence of cancer is expected to drive the growth of the in vitro diagnostics enzymes market in the coming years. Cancer is a group of diseases marked by the uncontrolled growth and spread of abnormal cells that can invade and damage healthy tissues. The occurrence of cancer is rising due to factors such as infectious agents, immune system dysfunction, and hormonal influences. The in vitro diagnostics enzymes market supports cancer care by enabling precise diagnostic assays for early detection, disease monitoring, treatment selection, and the advancement of personalized therapies. For example, in February 2024, according to the World Health Organization (WHO), a Switzerland-based intergovernmental organization, global cancer cases are projected to surpass 0.035 billion by 2050, reflecting a 77% increase from the estimated 0.02 billion cases reported in 2022. Therefore, the growing prevalence of cancer is fueling the expansion of the in vitro diagnostics enzymes market.
Major companies operating in the in vitro diagnostics enzymes market are concentrating on developing innovative solutions, such as autoimmune disorder detection kits, to broaden diagnostic capabilities, enhance early disease detection, and strengthen their market position. Autoimmune disorder detection kits are specialized diagnostic tools that utilize immunoassays, molecular techniques, and antibody detection technologies to identify autoantibodies and biomarkers associated with autoimmune conditions, enabling accurate and timely diagnosis. For instance, in September 2023, NeoDx Biotech Labs Pvt Ltd., an India-based manufacturer of in vitro diagnostic kits, introduced an autoimmune disorder detection IVD kit that integrates advanced immunoassays, molecular diagnostics, and precise antibody detection methods. This kit offers high sensitivity and specificity, helping clinicians achieve faster and more reliable diagnoses of autoimmune diseases.
In February 2023, SD Biosensor Inc., a South Korea-based in vitro diagnostics company, along with SJL Partners LLC, a South Korea-based investment firm, acquired Meridian Bioscience Inc. for $1.53 billion. This acquisition enhances SD Biosensor's global diagnostics portfolio by incorporating Meridian's expertise in diagnostic products and raw materials used in immunological and molecular testing. It also strengthens SD Biosensor's supply chain and technological capabilities by adding Meridian's in vitro diagnostic enzymes and assay development expertise. Meridian Bioscience Inc. is a US-based diagnostic company that supplies in vitro diagnostic enzymes.
Major companies operating in the in vitro diagnostics enzymes market are F. Hoffmann-La Roche Ltd., Thermo Fisher Scientific Inc., Danaher Corporation, Merck KGaA, Siemens Healthineers AG, Becton Dickinson and Company, Agilent Technologies Inc., Grifols SA, Hologic Inc., PerkinElmer Inc., bioMerieux SA, QuidelOrtho Corporation, Sysmex Corporation, Bio-Rad Laboratories Inc., Qiagen N.V., DiaSorin SpA, Promega Corporation, Randox Laboratories Ltd., Meridian Bioscience Inc., Fujirebio Diagnostics Inc., Sekisui Diagnostics LLC, Trivitron Healthcare, Amicogen Inc., EKF Diagnostics Holdings plc, Advanced Enzymes Technologies Ltd., Biocatalysts Ltd.
North America was the largest region in the in vitro diagnostics enzymes market in 2025. Asia-Pacific is expected to be the fastest-growing region in the forecast period. The regions covered in the in vitro diagnostics enzymes market report are Asia-Pacific, South East Asia, Western Europe, Eastern Europe, North America, South America, Middle East, Africa.
The countries covered in the in vitro diagnostics enzymes market report are Australia, Brazil, China, France, Germany, India, Indonesia, Japan, Taiwan, Russia, South Korea, UK, USA, Canada, Italy, Spain.
The in vitro diagnostics (IVD) enzymes market consists of revenues earned by entities by providing services such as enzyme engineering, custom enzyme production, validation services, promega custom assay services, and bio-techne enzyme solutions. The market value includes the value of related goods sold by the service provider or included within the service offering. The in vitro diagnostics (IVD) enzymes market also includes sales of Taq DNA polymerase, reverse transcriptase, alkaline phosphatase (ALP), horseradish peroxidase (HRP), DNA ligase, NEB enzyme products, and sigma-Aldrich diagnostic enzymes. Values in this market are 'factory gate' values, that is, the value of goods sold by the manufacturers or creators of the goods, whether to other entities (including downstream manufacturers, wholesalers, distributors, and retailers) or directly to end customers. The value of goods in this market includes related services sold by the creators of the goods.
The market value is defined as the revenues that enterprises gain from the sale of goods and/or services within the specified market and geography through sales, grants, or donations in terms of the currency (in USD unless otherwise specified).
The revenues for a specified geography are consumption values that are revenues generated by organizations in the specified geography within the market, irrespective of where they are produced. It does not include revenues from resales along the supply chain, either further along the supply chain or as part of other products.
In Vitro Diagnostics Enzymes Market Global Report 2026 from The Business Research Company provides strategists, marketers and senior management with the critical information they need to assess the market.
This report focuses in vitro diagnostics enzymes market which is experiencing strong growth. The report gives a guide to the trends which will be shaping the market over the next ten years and beyond.
Where is the largest and fastest growing market for in vitro diagnostics enzymes ? How does the market relate to the overall economy, demography and other similar markets? What forces will shape the market going forward, including technological disruption, regulatory shifts, and changing consumer preferences? The in vitro diagnostics enzymes market global report from the Business Research Company answers all these questions and many more.
The report covers market characteristics, size and growth, segmentation, regional and country breakdowns, total addressable market (TAM), market attractiveness score (MAS), competitive landscape, market shares, company scoring matrix, trends and strategies for this market. It traces the market's historic and forecast market growth by geography.
Added Benefits available all on all list-price licence purchases, to be claimed at time of purchase. Customisations within report scope and limited to 20% of content and consultant support time limited to 8 hours.